Purpose: To investigate anatomic changes in retinal thickness (RT) and functional changes after vitrectomy for idiopathic epiretinal membranes (ERMs) with and without internal limiting membrane (ILM) peeling. Methods: The medical records of 100 eyes of 96 patients with ERM who underwent vitrectomy and ERM removal were reviewed retrospectively. The RT was measured by optical coherence tomography, and the area was divided into 9 sections. The best-corrected visual acuity (BCVA), 9 RT areas, and incidence rates of recurrent ERM were compared between the groups with and without ILM peeling before the operation and 12 months postoperatively. Results: Thirty-nine eyes that underwent vitrectomy with ILM peeling and 61 eyes that underwent vitrectomy without ILM peeling met the inclusion criteria. There were no significant differences between the groups in the BCVA and any of the RTs before the operation and 12 months postoperatively. The ERMs recurred in 8 (20.5%) of 39 eyes and 26 (42.6%) of 61 eyes in the groups with and without ILM peeling, respectively, with a difference that reached significance (p = 0.02) 12 months postoperatively. Conclusions: Vitrectomy for ERM affects the BCVA or the RTs 12 months postoperatively. Additional ILM peeling does not affect them, but it might reduce the ERM recurrence rate.

Machmer R: A new concept for vitreous surgery. 7. Two instrument techniques in pars plana vitrectomy. Arch Ophthalmol 1974;92:407-412.
Michels RG: Vitrectomy for macular pucker. Ophthalmology 1984;91:1384-1388.
Margherio RR, Cox MS Jr, Trese MT, Murphy PL, Johnson J, Minor LA: Removal of epiretinal membranes. Ophthalmology 1985;92:1075-1083.
Rice TA, De Bustros S, Michels RG, Thompson JT, Debanne SM, Rowland DY: Prognostic factors in vitrectomy for epiretinal membranes of the macula. Ophthalmology 1986;93:602-610.
Pesin SR, Olk RJ, Grand MG: Vitrectomy for premacular fibroplasias. Prognostic factors, long-term follow-up, and time course of visual improvement. Ophthalmology 1991;98:1109-1114.
Grewing R, Mester U: Results of surgery for epiretinal membranes and their recurrences. Br J Ophthalmol 1996;80:323-326.
Donati G, Kapetanios AD, Pournaras CJ: Complications of surgery for epiretinal membranes. Graefes Arch Clin Exp Ophthalmol 1998;236:739-746.
Arnd G, Christos H, Renate S, Ricarda S, Fei Z, Anselm K: Residual cellular proliferation on the internal limiting membrane in macular pucker surgery. Retina 2012;32:477-485.
Oh HN, Lee JE, Kim HW, Yun IH: Clinical outcomes of double staining and additional ILM peeling during ERM surgery. Korean J Ophthalmol 2013;27:256-260.
Park DW, Dugel PU, Garda J, Sipperley JO, Thach A, Sneed SR, Blaisdell J: Macular pucker removal with and without internal limiting membrane peeling: pilot study. Ophthalmology 2003;110:62-64.
Kwok AKH, Lai TY, Yuen KS: Epiretinal membrane surgery with or without internal limiting membrane peeling. Clin Exp Ophthalmol 2005;33:379-385.
Kumagai K, Ogino N, Furukawa M, Hangai M, Kazama S, Nishigaki S, Larson E: Retinal thickness after vitrectomy and internal limiting membrane peeling for macular hole and epiretinal membrane. Clin Ophthalmol 2012;6:679-688.
Ripandelli G, Scarinci F, Piaggi P, Guidi G, Pileri M, Cupo G, Sartini MS, Parisi V, Baldanzellu S, Giusti C, Nardi M, Stirpe M, Lazzeri S: Macular pucker: to peel or not to peel the internal limiting membrane? A microperimetric response. Retina 2015;35:498-507.
Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B, Schuman JS, Swanson EA, Fujimoto JG: Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995;113:1019-1029.
Sivalingam A, Eagle RC Jr, Duker JS, Brown GC, Benson WE, Annesley WH Jr, Federman J: Visual prognosis correlated with the presence of internal-limiting membrane in histopathologic specimens obtained from epiretinal membrane surgery. Ophthalmology 1990;97:1549-5152.
Oh HN, Lee JE, Kim HW, Yun IH: Clinical outcomes of double staining and additional ILM peeling during ERM surgery. Korean J Ophthalmol 2013;27:256-260.
Pournaras CJ, Emarah A, Petropoulos IK: Idiopathic macular epiretinal membrane surgery and ILM peeling: anatomical and functional outcomes. Semin Ophthalmol 2011;26:42-46.
Lee JW, Kim LT: Outcomes of idiopathic macular epiretinal membrane removal with and without internal limiting membrane peeling: a comparative study. Jpn J Ophthalmol 2010;54:129-134.
Lim JW, Cho JH, Kim HK: Assessment of macular function by multifocal electroretinography following epiretinal membrane surgery with internal limiting membrane peeling. Clin Ophthalmol 2010;30:689-694.
Terasaki H, Miyake Y, Nomura R, Piao CH, Hori K, Niwa T, Kondo M: Focal macular ERGs in eyes after removal of macular ILM during macular hole surgery. Invest Ophthalmol Vis Sci 2001;42:229-234.
Balducci N, Morara M, Veronese C, Torrazza C, Pichi F, Ciardella AP: Retinal nerve fiber layer thickness modification after internal limiting membrane peeling. Retina 2014;34:655-663.
Ahn SJ, Ahn J, Woo SJ, Park KH: Photoreceptor change and visual outcome after idiopathic epiretinal membrane removal with or without additional internal limiting membrane peeling. Retina 2014;34:172-181.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.